Walvax Biotechnology Co., Ltd.
300142
Classement en actions
#4861
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical... Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
Prix de l'action
$1.87
Capitalisation boursière
$2.98B
Changement (1 jour)
-3.71%
Changement (1 an)
14.73%
Pays
CN
Échange Walvax Biotechnology Co., Ltd. (300142)
Catégorie
Healthcare
Revenus pour Walvax Biotechnology Co., Ltd. (300142)
Revenus en Jun 2026 TTM : $313.01M
Selon les derniers rapports financiers de Walvax Biotechnology Co., Ltd., le chiffre d'affaires actuel de l'entreprise (TTM) est de $313.01M. En 2024, l'entreprise a réalisé un chiffre d'affaires de $386.55M une diminution par rapport à le chiffre d'affaires de l'année 2023, qui était de $581.16M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Walvax Biotechnology Co., Ltd. de 2007 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $313.01M | -9.14% |
| 2025 | $344.50M | -10.88% |
| 2024 | $386.55M | -33.49% |
| 2023 | $581.16M | -21.19% |
| 2022 | $737.39M | 35.35% |
| 2021 | $544.82M | 21.10% |
| 2020 | $449.89M | 179.41% |
| 2019 | $161.02M | 26.68% |
| 2018 | $127.11M | 23.75% |
| 2017 | $102.71M | 20.66% |
| 2016 | $85.12M | -45.05% |
| 2015 | $154.92M | 33.46% |
| 2014 | $116.08M | 20.76% |
| 2013 | $96.13M | 11.51% |
| 2012 | $86.20M | 15.58% |
| 2011 | $74.58M | 37.20% |
| 2010 | $54.36M | 55.20% |
| 2009 | $35.03M | 29.85% |
| 2008 | $26.97M | 52.25% |
| 2007 | $17.72M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $23.54B | 7,419.13% |
DE
|
|
| $23.73B | 7,482.90% |
DE
|
|
| $29.24B | 9,241.55% |
JP
|
|
| $5.85B | 1,768.57% |
CH
|
|
| $6.34B | 1,926.24% |
IN
|
